The Fool and TipRanks are bullish on OptimizeRX. This is a small company with a valuation of under $1billion that has room to run.
February 26, 2021
On OptimizeRX
February 22, 2021
Looking at Guardant Health
The Fool looks at Guardant Health, which they have pegged as the leader in liquid biopsies. They have several products on the market and will launch additional products this year.
Waiting for Marqueta to go Public
One Fool is waiting for Marqueta to go public, which may happen around April. He explains why it is a top IPO stock to look forward to.
February 3, 2021
My Top Stock to Own for the Next 10 Years
CareTrust REIT is this Fool's top stock to own for the next 10 years.
February 1, 2021
On Vive Medical
This company’s products are very much in demand from women. Viveve Medical Inc. (NASDAQ: VIVE) designs, develops, manufactures and markets medical devices for the noninvasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation and stress urinary incontinence.
The Viveve System includes a radio frequency generator, reusable hand piece and treatment tip, as well as cryogen canister and other consumable components. The company markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East and Latin America.
The noninvasive, endovaginal Viveve system has been cleared and is marketed (by distribution partners) in more than 50 countries for a variety of noninvasive female health indications. The system also gained FDA clearance in late 2016, but only with a general surgical label. As of the end of third quarter 2020, the company had an installed base of 479 systems in the United States and 386 internationally.
Alliance Global has set a giant $10.75 target price. That compares with the much higher consensus target of $22. The stock has traded near $3.50 recently.January 25, 2021
On Intercept Pharma
The Fool has a small article on Intercept and why it may be a great turn around stock.
January 19, 2021
The Top 21 Stocks to Buy in 2021
The Fool has a list of 21 stocks to buy in 2021 along with an ETF and some SPACs.
13 Small Caps Poised to Become Mid Caps
IBD has a list of 13 small cap stocks that have the best chance to become mid cap stocks.
Subscribe to:
Posts (Atom)
